Subject: Nirsevimab notification

TVFC Provider:

Effective immediately, the Centers for Disease Control and Prevention (CDC) is moving to an allocation-based system for distribution of nirsevimab to public health. CDC indicates this shift is due to high demand and limited supply.

To accommodate this change, DSHS is pausing TVFC provider orders for nirsevimab in the Vaccine Allocation and Ordering System (VAOS) until further notice.

DSHS’s understanding from CDC is that Texas orders placed before October 9, 2023, are already being shipped. DSHS is awaiting confirmation on how CDC will handle orders placed after October 9, 2023.

CDC has indicated supplies will be limited and that CDC will focus distribution on states that have received little or no inventory to date. CDC expects to provide Texas with its first allocation next week but has not provided an exact timeline. CDC also indicates allocations will occur every two or three weeks after the initial allocation. Since Texas has been one of the largest requestors of nirsevimab to date, Texas may receive small allocations.

Providers with inventory should continue to report doses administered and wasted in VAOS. DSHS will need to develop its own allocation methodology to determine provider shipments. Especially if this scarcity continues for a lengthy time period, DSHS may need to use reported usage when making provider allocations.

DSHS will provide updates as information becomes available. Thank you for your understanding and partnership to vaccinate children in Texas.

Texas Department of State Health Services

Immunization Program